Domagrozumab

DB15083Investigational

Domagrozumab is under investigation in clinical trial NCT01616277 (A Phase 1 Study To Evaluate The Safety And Tolerability Of PF-06252616 In Healthy Subjects).

Mechanism: Pharmacologically active on Growth/differentiation factor 8
Curator reviewed
Also known as: PF-06252616

Resolves to

Compound

UNII516MD5WQ24CAS1629605-31-7

Targets

O14793MSTN

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Domagrozumab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account